living organisms. This class of enzymes is divided into two subclasses: FAD-containing amine oxidases (FAD-AOs) and Cu-containing amine oxidases (Cu-AOs). Two types of mitochondrial monoamine oxidases, monoamine oxidases (MAO)A and MAO-B, and cytosolic polyamine oxidase are included in FAD-AOs. The Cu-AOs consist of retina amine oxidase, diamine oxidase (DAO), and semicarbazide-sensitive amine ...

Monoamine oxidase (EC 1.4.3.4) exists in at least two forms (termed type A and type B) with different substrate and inhibitor specificities (Johnston, 1968; Knoll & Magyar, 1972). Amine neurotransmitters are among a wide range of substrates (Blaschko, 1974) and abnormalities of monoamine oxidase activity may therefore contribute to neurological disease. Most studies of such diseases have looked...

The monoamine oxiclases (MAO; EC 1.4.1.4), named by Zeller in 1938, are widely distributed in the animal kingdom (Blaschko, 1974; Hall and Uruena, 1983) and oxidize many biogenic and xenobiotic amines in the central nervous system and peripheral tissues. Thirty five years ago, MAO drew the attention of psychiatrists and pharmacologists when MAO inhibitors were found to be therapeutically effect...

Long-term depressive behavior was modeled via immunization of white rats with isatin (an endogenous MAO inhibitor) covalently bound to a carrier antigen. The immunization of rats against isatin and several exogenous MAO inhibitors (pargyline and deprenyl) resulted in long-term (2 months) depressive-like behavior with elements of anxiety and an increased activity of MAO in the brain. In contrast...

Introduct ion Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most frequent neurodegenerative disorders and cause of disability among western societies.1 Interest in the selective inhibition of monoamine oxidase B (MAO-B) has increased in the last years due to their therapeutic potential in this age related neurodegeneration. Currently, acetyl cholinesterase (AChE) inhibitors are ...

The EMSAM patch is a unique monoamine oxidase inhibitor (MAOI) being the only antidepressant utilizing a transdermal delivery system. This was welcomed by clinicians who hoped that EMSAM would be better tolerated than oral MAOIs and non-MAOI antidepressants, as well as being effective for treatment in a wide spectrum of depressed patients including atypical depression, bipolar depression, and r...